Screener
Integra LifeSciences IART Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000917520-26-000058
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $214,415 | $235,048 |
| Short-term investments | 59,669 | 28,693 |
| Trade accounts receivable, net of allowances of $7,326 and $7,230 | 267,188 | 278,849 |
| Inventories, net | 492,005 | 492,735 |
| Prepaid expenses | 104,344 | 96,089 |
| Other current assets | 53,861 | 28,130 |
| Total current assets | 1,191,482 | 1,159,544 |
Item 1. Financial Statements
FAQ
- What is Integra LifeSciences's accounts receivable?
- Integra LifeSciences (IART) reported accounts receivable of $267.19M in Q2 2026.
- How has Integra LifeSciences's accounts receivable changed year-over-year?
- Integra LifeSciences's accounts receivable decreased by 6.1% year-over-year, from $284.51M to $267.19M.
- What is the long-term trend for Integra LifeSciences's accounts receivable?
- Over 5 years (2020 to 2025), Integra LifeSciences's accounts receivable has grown at a 4.3% compound annual growth rate (CAGR), from $225.53M to $278.85M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Integra LifeSciences's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude